| scholarly article | Q13442814 |
| P50 | author | Robert Bucki | Q59551458 |
| Gregory Mendez | Q59744165 | ||
| Katarzyna Leszczyńska | Q59744175 | ||
| P2093 | author name string | P A Janmey | |
| E Won | |||
| W Sokołowski | |||
| P B Savage | |||
| A Namiot | |||
| K Cruz | |||
| F J Byfield | |||
| P2860 | cites work | Ceragenins: a class of antiviral compounds to treat orthopox infections. | Q53390059 |
| Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines | Q54671540 | ||
| Synergistic and additive killing by antimicrobial factors found in human airway surface liquid | Q56960106 | ||
| Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens | Q57275273 | ||
| A new test based on 'salting out' to measure relative surface hydrophobicity of bacterial cells | Q64452078 | ||
| Problems in determination of antibiotic synergism in vitro | Q70258090 | ||
| Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37 | Q77630845 | ||
| Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats | Q77941051 | ||
| Antimicrobial activities of amine- and guanidine-functionalized cholic acid derivatives | Q28343347 | ||
| Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice | Q33499892 | ||
| Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. | Q33883780 | ||
| Direct continuous method for monitoring biofilm infection in a mouse model | Q34581327 | ||
| Bacterial and fungal biofilm infections | Q34701119 | ||
| The antimicrobial activity of non-antibiotics. Report from a congress on the antimicrobial effect of drugs other than antibiotics on bacteria, viruses, protozoa, and other organisms | Q35211585 | ||
| Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus | Q35758983 | ||
| Microbiology of airway disease in patients with cystic fibrosis | Q36636914 | ||
| Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. | Q36701086 | ||
| The bacterial envelope as a target for novel anti-MRSA antibiotics | Q37080463 | ||
| Topical antimicrobials in pediatric burn wound management. | Q37225237 | ||
| Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents | Q37287220 | ||
| Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. | Q37324151 | ||
| Anti-trypanosomatid activity of ceragenins | Q39767506 | ||
| Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum | Q40116758 | ||
| Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci | Q40133451 | ||
| Cationic steroid antibiotics demonstrate DNA delivery properties | Q40380786 | ||
| Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin | Q40815963 | ||
| Effects of pluronic F-127 on loading of fura 2/AM into single smooth muscle cells isolated from guinea pig taenia coli | Q42118328 | ||
| Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes | Q42144931 | ||
| Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms | Q42972145 | ||
| A series of cationic sterol lipids with gene transfer and bactericidal activity. | Q43100806 | ||
| Enhancement of vancomycin activity by phenothiazines against vancomycin-resistant Enterococcus faecium in vitro | Q43114674 | ||
| Assessing peri-implant tissue infection prevention in a percutaneous model | Q43238273 | ||
| Ceragenins: cholic acid-based mimics of antimicrobial peptides | Q43656859 | ||
| Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens | Q43907044 | ||
| Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis | Q44001143 | ||
| The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin | Q44296193 | ||
| Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria | Q44589066 | ||
| Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa | Q44647314 | ||
| Penetration of a selected antibiotic and antiseptic into a biofilm formed on orthopedic steel implants. | Q44683446 | ||
| Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo | Q44828758 | ||
| Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. | Q46554964 | ||
| Use of autologous tissue engineered skin to treat porcine full-thickness skin defects. | Q46714905 | ||
| Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates | Q46835624 | ||
| Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics | Q50111437 | ||
| Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. | Q51084969 | ||
| Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an Intensive Care Unit. | Q51763620 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 229-238 | |
| P577 | publication date | 2010-10-21 | |
| P1433 | published in | Journal of Applied Microbiology | Q15756992 |
| P1476 | title | Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections | |
| P478 | volume | 110 |
| Q43201096 | Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections |
| Q88004859 | Antibacterial and Antifungal Activities of Poloxamer Micelles Containing Ceragenin CSA-131 on Ciliated Tissues |
| Q36076086 | Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection. |
| Q35689986 | Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles. |
| Q36055572 | Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites. |
| Q37361845 | Core-shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins |
| Q34809662 | Evolution of antimicrobial peptides to self-assembled peptides for biomaterial applications |
| Q33870762 | Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13. |
| Q33874753 | In vitro bactericidal and bacteriolytic activity of ceragenin CSA-13 against planktonic cultures and biofilms of Streptococcus pneumoniae and other pathogenic streptococci |
| Q35198896 | N-terminally modified linear and branched spermine backbone dipeptidomimetics against planktonic and sessile methicillin-resistant Staphylococcus aureus |
| Q33909499 | Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus |
| Q35654991 | Polyelectrolyte-mediated increase of biofilm mass formation |
| Q37704569 | Sporicidal activity of ceragenin CSA-13 against Bacillus subtilis. |
| Q37872942 | Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria |
| Q35091629 | Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37 |
| Q64069992 | Use of ceragenins as a potential treatment for urinary tract infections |
Search more.